Introduction
============

Dendritic cells (DCs) are a heterogeneous population of rare hematopoietic cells that are present in most tissues and are essential to the induction of both immunity and tolerance (Steinman and Witmer, [@B108]; Birnberg et al., [@B16]; Ohnmacht et al., [@B85]). They are organized as a specialized "network" that enables them to sample antigens from their environment which are then presented to other lymphocytes. As such, this elegant arm of the immune system is dedicated to shaping the immune response to peripheral antigens.

Dendritic cells are distinct from other immune cells as they are equipped with molecular machinery that enables them to very efficiently take up, process, and present antigens on major histocompatibility (MHC) class I and II molecules to T cells. In addition, they are equiped with a range of pathogen sensing molecules such as toll-like receptors (TLRs), nucleotide-binding oligomerization domain proteins, retinoid-inducible gene 1-like receptors, and C-type lectins that allow them to detect pathogen products and sense inflammation. Signaling through these receptors triggers migration of DCs from peripheral tissues to secondary lymphoid organs bringing DCs carrying antigens into close association with T cells. This pathway provides the critical link between the external environment (the major entry point for pathogens) and the sites where organized immune responses are induced, the lymph nodes (Randolph et al., [@B90]).

In recent years a number of distinct DC subsets have been defined. These subsets have been based largely on long standing criteria that relies on the expression of specific cell-surface markers. More recently, understanding the development and contributions of these DC subsets to immunity has been broadened significantly by insights to the ontogeny of the different subsets and the transcription factors that guide their development. Here we will highlight recent studies deciphering the transcriptional regulation that underpins DC heterogeneity which is critical in defense against pathogen infection.

Architecture of the DC Network
==============================

On the October 3, 2011, DCs took center stage in the scientific world with the awarding of the Nobel Prize for Physiology or Medicine to Ralph Steinman together with Bruce Beutler and Jules Hoffmann for revolutionizing our understanding of the immune system by discovering key principles for its activation. Hoffman pioneered the discovery of sensing molecules in fruit flies enabling them to combat infection (Lemaitre et al., [@B66]), while Beutler uncovered the homologous receptors in mice that could detect pathogen products (Poltorak et al., [@B88]). More than a decade earlier, Ralph Steinman had discovered a rare cell type, the DC, within the immune system that had a unique capacity to efficiently activate immune cells (Steinman and Cohn, [@B107]). Since then, it has been shown that DCs express a wide range of innate receptors that enable pathogen sensing and the initiation of protective immunity.

Cardinal features of DCs are (i) their ability to efficiently take up and present self and pathogen-derived antigens to other cells of the immune system such as T cells and B cells, and (ii) their capacity to migrate from peripheral tissues such as skin and mucosa to secondary lymphoid tissues where they can activate lymphocytes and initiate the immune response. This migratory behavior is pivotal and provides a critical cellular link between the external environment where pathogens might enter the body and the secondary lymphoid tissues where immune responses are initiated.

A signature of DCs is their heterogeneity. The DC network is composed of multiple subtypes of DCs that vary in their origin, anatomical localization, lifespan, and function (Figure [1](#F1){ref-type="fig"}). Unraveling the developmental history of these subtypes has been complicated in part by the rarity of DCs in tissues (∼1% of cells) and their short lifespan. This was compounded by the early difficulties in establishing the growth factors and culture conditions necessary for generating large numbers *in vitro*. However, recent studies have made significant progress in clarifying a number of these steps.

![**Architecture of the DC network**. The DC network is composed of multiple DC subsets that are broadly divided into cDCs, pDCs, MoDCs, and LCs which have distinct anatomical localizations in tissues. **(A)** Migratory DCs in peripheral tissues sample antigen from the periphery and then migrate through the lymphatic vessels to the afferent lymph node to present captured-processed antigens to the T cell within the T cell zone. In peripheral tissues, such as the skin, three main DC subsets are found. Dermal DCs are composed of the CD103^+^CD11b^−^ DC and CD11b^+^ DC. Both arise from a pre-DC that homed to the tissue. Under conditions of inflammation, some CD11b^+^ DC can be derived from a monocytic precursor. In addition to the dermal DCs, the epidermis of the skin is populated by the LCs which are derived from a Ly6C^+^ progenitor. **(B)** In secondary lymphoid tissues such as spleen, CD4^+^, CD8α^+^, and CD4^−^CD8α^−^ or double negative (DN) DCs are found. These subsets are also found in the draining lymph nodes which also receive the influx of the migratory CD11b^+^, CD103+CD11b^−^ DCs, and LCs arriving from the peripheral tissues.](fimmu-03-00026-g001){#F1}

Simplistically, four major populations of DCs have been described (Figure [1](#F1){ref-type="fig"}), namely the conventional DCs (cDCs), plasmacytoid DCs (pDCs), Langerhans cells (LCs), and the monocyte-derived DCs (MoDCs).

Conventional DCs
----------------

Conventional DCs can be divided into two main groups of cells. They are (i) the *migratory* DCs and (ii) the *lymphoid tissue-resident* DCs (Figure [1](#F1){ref-type="fig"}).

Migratory DCs reside in peripheral tissues such as the skin and mucosa where they efficiently sample environmental antigens and then migrate from to the regional lymph node in afferent lymphatics to present antigens to T cells. They are composed of the dermal or interstitial DCs and can be divided into the CD11b^+^ and CD11b^−^ DCs (Figure [1](#F1){ref-type="fig"}A). These DCs may also express the integrin αE, also known as CD103. CD103 is expressed on CD11b^−^ DCs and can be found in a variety of others tissues. However, in intestinal tissues, CD103 is expressed on CD11b^+^ DCs. Despite a similarity in expression of surface molecules by these two DC subsets, the transcriptional machinery regulating these two populations is distinctly different as discussed below.

The second category of cDCs is composed of several subsets of DCs that are known as *tissue-resident DCs*. In contrast to their migratory counterparts, they do not circulate through peripheral tissues and thus can only process antigens found within the tissue in which they are localized (Figure [1](#F1){ref-type="fig"}B). To overcome this potentially limited access to antigen, migratory DCs can transfer antigens to lymphoid resident DCs who via the process of *cross-presentation*, provide an alternate strategy for the amplification of CD8^+^ T cell responses (Belz et al., [@B14]; Allan et al., [@B4]).

Tissue-resident DCs are delineated by the expression of the surface molecules CD4 and CD8α and are found in secondary lymphoid organs such as the thymus, spleen, and lymph nodes. Three subsets have been defined which are (i) the CD4^+^ DCs, (ii) the CD8α^+^ DCs, and (iii) the CD4^−^CD8α^−^ (double negative, DN) DCs. These subsets develop *in situ* from a common precursor generated in the bone marrow that homes to the lymphoid organs where they undergo further differentiation into mature DC subsets (Naik et al., [@B81]). Although there are a number of shared functions between these subsets, an interesting division of labor has emerged: CD8α^+^ DCs are highly efficient in direct and cross-presentation of soluble, cell-associated (Table [1](#T1){ref-type="table"}), and pathogen-derived antigens to CD8^+^ T cells. Although CD4^+^ DCs and CD4^−^CD8α^−^ DCs can also present MHC class I-restricted antigens in some settings (Kim and Braciale, [@B63]; Lukens et al., [@B71]). They are more potent in presenting MHC II antigens to CD4^+^ T cells (Allenspach et al., [@B5]; Mount et al., [@B78]).

###### 

**Features of cross-presenting antigen presenting cells**.

  DC Subset                                                                                                                                                     
  -------------------------------------- ------------------------------------------ ------------------------------------------ -------------------------------- --------------------------------------------------------------------
  XCR1                                   **+**                                      **+**                                      n.d.                             Dorner et al. ([@B33])
  Clec9a                                 **+**                                      **+**                                      −                                Caminschi et al. ([@B21]), Sancho et al. ([@B93]),
                                                                                                                                                                Hashimoto et al. ([@B49])
  Mannose receptor                       **+**                                      n.d.                                       n.d.                             Burgdorf et al. ([@B18])
  CD36                                   **+**                                      \+                                         \+                               Albert et al. ([@B1]), Belz et al. ([@B12]), Desch et al. ([@B32])
  E-cadherin                             n.d.                                       n.d.                                       **+**                            Siddiqui et al. ([@B103])
  TLR3                                   **+**                                      **+**                                      n.d.                             Schulz et al. ([@B101]), Jelinek et al. ([@B59])
  Cytochrome *c*/Apaf-1 mediated death   **+**                                      n.d.                                       n.d.                             Lin et al. ([@B69])
  Migratory                              No                                         Yes                                        n.t.                             del Rio et al. ([@B29])
  Involved in pathogen infection         Yes                                        Yes                                        Yes                              Belz et al. ([@B15]), Allan et al. ([@B4]), Bedoui et al. ([@B10])
  Cross-presentation                     Constitutive soluble and cell-associated   Constitutive soluble and cell-associated   Induced in inflammation (TLR4)   den Haan et al. ([@B31]), Jackson et al. ([@B58])

*n.d., Not determined*.

### CD8α^+^ and CD103^+^ DCs -- drivers of cross-presentation

The CD8α^+^ and CD103^+^ DCs are cDCs that are of special interest due to their shared functional attributes in driving immune responses to pathogen infections, their capacity to cross-present antigens, and the potential to harness the human equivalents of these subsets for clinical use (Steinman, [@B106]). What distinguishes these two subsets functionally and transcriptionally has thus been an area of intense investigation.

#### The CD8α^+^ DC subset

CD8α^+^ DCs are distinct from other conventional murine DC subsets by their unique surface expression of a CD8αα homodimer. This non-migratory, lymphoid tissue-resident DC has been shown to be key drivers of cross-presentation to a range of experimental pathogen antigens both *in vitro* and *in vivo*. CD8α^+^ DCs have been found to be critical for cross-presentation of self-antigens resulting in the induction of immune tolerance (Belz et al., [@B11]; Heath et al., [@B50]). This subset was also identified as the main subset involved in presenting pathogen-derived antigens (Allan et al., [@B3]; Belz et al., [@B14],[@B15], [@B13]; Lemos et al., [@B67]; Neuenhahn et al., [@B84]; Edelson et al., [@B36]). A number of mechanisms have been proposed to explain their constitutive ability to cross-present antigens. These include the expression of a number of surface receptors, such as CD36 and Clec9a, that allow them to uptake dead or dying cells, specialized intracellular pathways, and regulation of the pH in the phagosome (Table [1](#T1){ref-type="table"}). This antigen presenting function and their production of interleukin-12 (IL-12) distinguish the CD8α^+^ DCs from their CD8α^−^ counterparts. Although initially cross-presentation by CD8α^+^ DCs was thought to be a unique property restricted solely to this subset, it is now clear that other DC subsets can act as potent cross-presenting cells (i.e., CD103^+^ DC subset and MoDCs, Table [1](#T1){ref-type="table"}).

#### The CD103^+^ DC subset

This unusual DC subset that appeared to be related to CD8α^+^ DCs was first described in the influenza infection and was characterized by the lack of expression of CD8α and CD11b (CD8α^−^CD11b^−^; Belz et al., [@B15]). It was found in a number of lymph nodes including the inguinal, brachial, superficial cervical, mediastinal, mesenteric, hepatic, and renal nodes. This DC subset presents viral antigens very efficiently suggesting that CD8α^−^CD11b^−^ DCs may play an important role in T cell mediated immunity. It was postulated that these cells could traffic to the lymph nodes, thereby providing a critical link between antigen sampling in peripheral tissues and antigen presentation in the lymph node. Furthermore it was speculated that these cells would be capable of cross-presentation. Following this early report, it was discovered that these DCs expressed the molecules integrin α~E~ (CD103) and langerin (Sung et al., [@B109]). Following on from the establishment of the importance of CD8α^+^ DC in promoting viral immunity (Allan et al., [@B3]), CD103^+^ (langerin^+^) dermal DCs, and lung CD103^+^ DCs have emerged as a potent migratory DC able to process and load self- and viral antigens onto MHC class I molecules (Sung et al., [@B109]; Bedoui et al., [@B10]).

Plasmacytoid DCs
----------------

Plasmacytoid DCs express several key molecules that distinguish them from the cDC subsets. These include the sialic acid-binding immunoglobulin like lectin H (Siglec-H), Lilra4 (also known as ILT7), bone marrow stromal antigen-2 (BST2, also known as tetherin) and blood DC antigen-2 (BDCA-2, also known as CLEC4C), and the CD45RA isoform (Reizis et al., [@B92]). The hallmark property of pDCs is their capacity to rapidly secrete type I interferons (IFN-α) during viral infection. This is in part attributable to their expression of TLR7 and TLR9 that enables sensing of nucleic acids during viral infection. The antigen presentation potency of pDCs is poor and although this can be enhanced during maturation (Colonna et al., [@B27]), their low expression of MHC and co-stimulatory molecules compared to their cDCs counterparts provide some explanation for their inefficiency in priming of T cells.

Langerhans cells
----------------

Langerhans cells are a unique DC subset found within the epidermis of the skin and mucosa and contain large tennis racquet shaped granules known as Birbeck granules of which langerin is a crucial component. Initially, it was thought that langerin expression was restricted solely to LCs, but it has more recently been discovered that DC subsets located in the lamina propria of skin, bronchi, and mucosa also express langerin (Bursch et al., [@B20]; Ginhoux et al., [@B44]; Poulin et al., [@B89]). Despite sharing the expression of langerin, other langerin^+^ DCs can arise along a different developmental pathway distinct from LCs (Merad et al., [@B77]). LCs develop from a local LY6C^+^ myelo-monocytic precursor cell population, and their development is dependent on TGF-β signaling (Chorro et al., [@B25]; Nagao et al., [@B79]), while langerin^+^ DC develop from a bone marrow precursor that is dependent on Fms-like tyrosine kinase 3 (Flt3) signaling. LCs are exquisitely positioned to provide the front line of defense of the immune system against external invading pathogens. As LCs are the only cells that express MHC II in the epidermis under non-inflammatory conditions and since they are able to migrate through the dermis to the skin-draining lymph nodes, LCs have been believed to be critical to promote immunity, i.e., after skin infection.

This classical paradigm has been recently challenged. LCs are largely resistant to γ-irradiation, a characteristic that has been taken advantage of in deciphering the immunological relevance of LC over dermal DC in chimeric mice. This feature has allowed the generation of elegant chimeric mice in which LCs could be of host origin while dermal and other DCs were of donor origin. Thus the individual function of LCs could be addressed. LCs were found to be unable to initiate T cell dependent immunity when challenged with a herpes simplex virus (HSV) type 1 skin infection (Allan et al., [@B3]). Similarly, LCs from the vaginal mucosa are not able to present HSV type 2-derived antigens to CD4^+^ T cells (Zhao et al., [@B118]). Although the biological function of LCs *in vivo* still raises much debate, it is now clearer that a major role of LCs is in maintaining immune tolerance (Shklovskaya et al., [@B102]).

Monocyte-derived DCs
--------------------

Under non-inflammatory conditions, monocytes can give rise to CD11b^+^ MoDCs in non-lymphoid organ, and their development is in part dependent on MCSF-R signaling (Bogunovic et al., [@B17]; Ginhoux et al., [@B45]). However the contribution of monocytes to the DC pool is by far more important under inflammatory condition. Pathogen recognition by CD11c^−^MHCII^−^ blood monocytes leads to their differentiation into CD11c^+^MHCII^+^ MoDCs that express GR1/LY6C pointing to their monocytic origin (Leon et al., [@B68]; Hohl et al., [@B53]; Nakano et al., [@B83]), becoming thereafter the dominant DC population. Until recently, the contributions of MoDCs to pathogen infections have been largely ignored. Recent detailed analyses of their antigen-capturing, processing, and presentation capacity revealed that they are strikingly efficient at both direct and cross-presentation of antigens and at least under certain conditions as good as CD8α and CD103^+^ DCs (Cheong et al., [@B24]). Under inflammatory conditions, MoDCs have been found to be the main population presenting antigens in the T cell area (Ingersoll et al., [@B57]). Hence, blood monocytes serve as an emergency reservoir of antigen presenting cells that efficiently recognize pathogens and their associated danger signals and rapidly induce specialized antigen presentation machinery. Based on the short kinetic of differentiation observed *in vivo*, it is likely that so called "DC genes" are poised to enable rapid differentiation into MoDCs to efficiently counter pathogen attack. The characterization of new markers that clearly identify MoDCs from cDCs in inflamed tissues will open the door for a better understanding of the molecular mechanisms that drive monocyte differentiation into MoDCs (Cheong et al., [@B24]; Siddiqui et al., [@B103]).

DC development
--------------

### Ontogeny

The hematopoietic system is hierarchically organized (Figure [2](#F2){ref-type="fig"}). Long-term repopulating hematopoietic stem cells (HSC) constantly self renew but can also give rise to short-term repopulating cells that have lost much of their self-renewal capacity. These precursors differentiate further into the multi-lineage progenitor (MPP). MPP can give rise to both the common-lymphoid progenitor (CLP) and the common myeloid progenitor (CMP). Both CLP and CMP can differentiate into several DC subsets (Manz et al., [@B73]). This dual origin of DCs has provoked controversy in the field. However, recent studies have clarified the origin of DCs. Under steady-state conditions, the two main populations of DCs, the cDCs and pDCs, have both been shown to arise from a common dendritic cell precursor (also called the CDP) found in the bone marrow. CDPs are devoid of macrophage potential and exclusively give rise to DCs *in vitro* and *in vivo* (Naik et al., [@B82]; Onai et al., [@B86]). Once generated CDPs develop either into pDCs in the bone marrow, or give rise to pre-cDCs that are able to migrate from bone marrow to lymphoid and non-lymphoid organs to further mature into cDCs (Naik et al., [@B81]). The CDP is thought to originate from a bipotential macrophage/DC progenitor (MDP) that can generate either DCs or macrophages (Fogg et al., [@B40]).

![**Ontogeny of DC precursors**. Short-term HSCs commit into multipotent progenitors that give rise to either a common-lymphoid progenitor (CLP) or a common myeloid progenitor (CMP). A population that lies downstream of CMP has been found to differentiate either into DC or macrophages, and was therefore named the macrophage-dendritic cell progenitor (MDP). Full commitment to the DC lineage is acquired at the CDP stage (common DC progenitor) where a CDP can either differentiate into plasmacytoid DCs (pDCs) or into a pre-DC. The latter will further differentiate into mature conventional DCs (cDCs) in the peripheral tissues, or secondary lymphoid organs.](fimmu-03-00026-g002){#F2}

Extracellular Cues Driving DC Development
=========================================

Development of early DC precursors is directed by the interplay between extrinsic cytokine signals such as Flt3, macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and transcription factors PU.1, Ikaros, and Gfi-1. A key determinant of the development of DC precursors at steady-state is the Flt3:Flt3L pathway. Mice that lack Flt3L, or its receptor Flt3, have a severe reduction in conventional and pDC subsets (McKenna, [@B76]; Waskow et al., [@B114]). Conditional expression, or exogenous administration of Flt3L, results in a dramatic expansion of DCs in secondary lymphoid tissues (Maraskovsky et al., [@B74]; Manfra et al., [@B72]). Thus, Flt3 and Flt3L are pivotal in driving DC ontogeny. Coordinate regulation of Flt3 signaling is mediated through Stat3 but is dispensable for differentiation of DCs via GM-CSF signaling which is important for driving the differentiation of monocyte-derived DC development in an inflammatory setting (Laouar et al., [@B65]; Onai et al., [@B87]).

The growth factor M-CSF is well known to promote the development of macrophages and monocytes. The first example for a function of M-CSF in DC development was uncovered by Ginhoux et al. ([@B46]), who found that mice lacking the M-CSFR failed to generate LCs, highlighting the critical role of M-CSFR/M-CSF axis in the generation of this unique DC subset. Although this pathway is thought to be dispensable for the generation of cDC and pDC, recently, a novel role for M-CSF in DC development has been uncovered. pDCs and cDCs can be generated from *Flt3L^−/−^* bone marrow cells when cultured in presence of M-CSF (Fancke et al., [@B39]). In addition the injection of M-CSF into mice leads to increased pDCs and cDCs numbers. Nevertheless, the effect of M-CSF on steady-state DCs (except from the LC) is modest when compared with the influence of Flt3 in steady-state DC development. The M-CSFR/M-CSF axis would be predicted to be more critical in the generation of MoDCs during a pathogen attack, but this pathway remains to be fully elucidated.

Transcription Factors Driving DC Development
============================================

Transcription factors regulating early DC development
-----------------------------------------------------

The differentiation of hematopoietic precursor cells into different DC lineages is a well orchestrated process controlled in large part by transcription factors that are modulated by extracellular cues such as cytokines. The transcriptional networks that guide the development of B and T cells, particularly in early hematopoiesis, are relatively well defined. In contrast, the transcription factors that specifically regulate DC differentiation have only now begun to be elucidated. This has been facilitated by the use of lineage-specific knockout mice and elegant lineage tracing approaches.

These transcription factors can be broadly divided into those that are required or act early in DC development in DC progenitors (Gfi-1, Pu.1), and those whose major actions affect DC subset specification late in DC development (E2.2, Spi-B, IRF8, Id2, Nfil3, Batf3).

### Gfi-1

Gfi-1 is a zinc-finger critical for DC ontogeny. Mice lacking Gfi-1 show a global reduction in DC numbers but increased frequency of LCs (Rathinam et al., [@B91]). Interestingly, *Gfi-1^−/−^* bone marrow progenitors cultured *in vitro* in presence of Flt3L or GM-CSF fail to produce DC and instead develop into macrophages. Gfi-1 antagonizes PU.1 activity through direct protein interaction and it seems plausible that the aberrant macrophage potential observed in *Gfi-1^−/−^* bone marrow progenitors reflects failed repression of PU.1 binding to its positive regulatory elements, resulting in a macrophage rather than a DC fate (Spooner et al., [@B105]).

### PU.1

PU.1 (encoded by the gene *Sfpi1*) belongs to the Ets family of transcription factors. Until recently, its role in DCs has been unclear due to disparate studies -- the first reporting a deficit in DC differentiation (Anderson et al., [@B7]) and the second reporting apparently normal DC development in the absence of PU.1 (Guerriero et al., [@B47]). These studies could not distinguish whether PU.1 played a role at the stage of DC commitment or whether its main action was in multipotent progenitors. Conditional deletion of PU.1 at different stages of DC development highlighted the requirement of PU.1 for DC commitment as differentiation was abrogated in absence of PU.1 (Carotta et al., [@B22]). Furthermore, PU.1 lies upstream of FLT3 and GM-CSFR and is required for the development of DCs via both pathways. Thus, PU.1 is a central player in the generation of both steady-state DCs and presumably inflammatory DCs although the complex interactions of PU.1 in coordinating DC differentiation remain to be fully explored.

Transcription factors regulating late DC differentiation
--------------------------------------------------------

While a number of transcription factors delineate the development of precursor cells that ultimately give rise to DCs, specification of individual DC subset identity appears to be a late event that is guided a handful of transcription factors (see Table [2](#T2){ref-type="table"}). These can be broadly divided into three pathways of regulation -- those transcription factors that predominantly influence (i) the pDCs (namely E2-2 and Spi-B), (ii) the CD8α^+^ and CD103^+^ lineages (IRF8, Id2, EB4BP, and Batf3), and (iii) the non-CD8α^+^ DC lineages (IRF2, IRF4).

###### 

**Transcription factors guiding steady-state DC subset development**.

  Transcription factor   Transcription factor family                                                     Phenotype                                                                                                   Reference
  ---------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  *PU.1 (SPI1, Sfpi1)*   Ets-domain transcription factor binds to PU box sequences                       Required for development of all DC subsets                                                                  Anderson et al. ([@B7]), Guerriero et al. ([@B47]), Carotta et al. ([@B22])
  *Irf2*                 Interferon regulatory factor, inhibits the IRF1-mediated activation of IFNα/β   Alters pDC ratios; reduction in CD8^−^ DCs and LCs                                                          Ichikawa et al. ([@B56])
  *Irf4*                 Interferon regulatory factor                                                    Required for non-CD8α^+^ DC lineage development                                                             Suzuki et al. ([@B110]), Tamura et al. ([@B112])
  *Irf8 (ICSBP)*         Interferon regulatory factor                                                    Required for pDC and most cDC development                                                                   Schiavoni et al. ([@B97]), Aliberti et al. ([@B2]), Tsujimura et al. ([@B113]), Schiavoni et al. ([@B96]), Tailor et al. ([@B111])
  *Gfi-1*                Zinc-finger protein, repressor                                                  50% reduction in cDC and pDC subsets and increased LCs                                                      Rathinam et al. ([@B91])
  *Id2*                  Inhibitor of DNA-binding family containing helix-loop-helix domains (HLH)       Required for development of CD103^+^ DCs and CD8α^+^ DCs in PLN and spleen; not required for DCs in MLNs.   Hacker et al. ([@B48]), Ginhoux et al. ([@B45]), Jackson et al. ([@B58])
  *E4BP4 (NFIL3)*        PAR-related basic leucine zipper (bZIP) transcription factor                    Required for development of CD8α^+^ DCs                                                                     Kashiwada et al. ([@B62])
  *E2-2 (Tcf4)*          E protein containing basic helix-loop-helix domains (bHLH)                      Required for development of pDCs and their maintenance                                                      Cisse et al. ([@B26]), Ghosh et al. ([@B42])
  *Stat3*                Signal transducer and activator of transcription                                Significant reduction in cDCs                                                                               Laouar et al. ([@B65])
  *Stat5a/b*             Signal transducer and activator of transcription                                Inhibits pDC development by interacting with *Irf8*, reduced cDC and pDC subsets                            Esashi et al. ([@B38])
  *Ikaros (Ikzf1)*       Zinc-finger DNA-binding protein                                                 Absence of most DCs. pDCs specifically lost in hypomorphic mutant                                           Wu et al. ([@B117]), Allman et al. ([@B6])
  *Batf3*                bZIP, heterodimerizes with Jun                                                  Failure to develop CD103^+^ DCs; impaired survival of precursor CD8α^+^ DCs                                 Hildner et al. ([@B52]), Edelson et al. ([@B37]), Jackson et al. ([@B58])
  *RelB*                 Rel homology domain family, interacts with NFκB family                          Loss of CD8^−^ DCs                                                                                          Burkly et al. ([@B19]), Wu et al. ([@B116])
  *SpiB*                 Ets-domain transcription factor                                                 Required for human pDC differentiation                                                                      Schotte et al. ([@B100])

### Regulation of pDCs by E2-2

E proteins constitute a family of basic helix-loop-helix (bHLH) transcription factor whose function have been most clearly defined in B lymphocytes (de Pooter and Kee, [@B28]). The expression of E proteins is modulated by inhibitor of DNA-binding (ID) proteins which can bind E proteins to prevent their binding to DNA targets. To date three mammalian E proteins have been described (E2a, HEB, E2-2) that act on their targeted sequence (CACCTG E-box) either as homodimers or heterodimers. The first indication that E proteins played important roles in pDC differentiation came from the study by Spits et al. ([@B104]), where the overexpression of Id proteins, which sequester E proteins, impaired *in vitro* pDC development but left cDC differentiation intact. Subsequent analysis uncovered that E2-2, encoded by the gene *Tcf4*, was a key determinant of pDC differentiation. Germline or conditional deletion of E2-2 led to a complete loss of the pDC and abolished the ability of mice to respond to unmethylated DNA (Cisse et al., [@B26]). Through the binding of E2-2 to many pDC signature genes (*Irf8, Irf7, SpiB, BDCA-2*) it has been proposed as a master regulator of the pDC compartment. In line with this hypothesis, the depletion of E2-2 in mature pDC led to a predominance of cDC-like cells implying that E2-2 plays a pivotal role in maintaining pDC cell fate (Ghosh et al., [@B42]). However, in this setting it is difficult to separate the contribution of expansion of the pre-existing cDCs as molecular analyses showed enrichment of the conventional DC genes rather than a pure signature. Nevertheless, pDCs are particularly sensitive to E2-2 concentration as both E2-2-deficient mice and rare patients with haploinsufficiency (Pitt--Hopkins syndrome) show impaired pDC formation and function (Cisse et al., [@B26]).

### Spi-B

A second transcription factor that influences the development of pDCs is Spi-B, a member of Ets family transcription factor (Schotte et al., [@B100]). In contrast to the loss of PU.1, deficiency of Spi-B affects only the pDC compartment. Interestingly, over expression of Spi-B in human pDCs impairs Id2 expression and consequently E2-2 activity is enhanced suggesting that Id2 is a key regulator of the cDC/pDC balance (Nagasawa et al., [@B80]). However, the capacity for E2-2 to promote pDC differentiation was abolished in these DC when Spi-B expression was ablated showing that Spi-B and E2-2 are jointly necessary to efficiently drive development of human precursors into the pDC lineage (Nagasawa et al., [@B80]).

The IRF8--ID2--BATF3 axis regulates classical cross-presenting DCs
------------------------------------------------------------------

### IRF8

Interferon regulatory factor 8 (also called the interferon consensus sequence-binding protein, or ICSBP) regulates the development of both cDCs and pDCs and is highly expressed on the CDP. Mice deficient in IRF8 lack many mature DC subsets including CD8α^+^ DCs and LCs (Schiavoni et al., [@B97], [@B96]). In addition, IRF8 controls functional features such as TLR9 and IFN-α production in pDCs and IL-12 production in CD8α^+^ DCs (Tailor et al., [@B111]). *Irf8^−/−^* mice are more susceptible to viral infection but also develop a myeloproliferative syndrome characterized by overproduction of granulocytes (Holtschke et al., [@B54]). This suggests that while IRF8 is important for conventional DC development, it may also be required for the generation or maintenance of the upstream MDP progenitor that can give rise to monocytes, cDCs, and pDCs.

### Id2

The expression of Id2 is highest in CD8α^+^ and CD103^+^CD11b^−^ DCs but it is nevertheless broadly expressed by all conventional DC subsets (Ginhoux et al., [@B45]; Jackson et al., [@B58]). Loss of Id2 results in the failure of these two subsets, CD8α^+^ and CD103^+^ DCs, to develop in skin-draining lymph nodes and spleen. CD103^+^CD11b^+^ DCs found in the lymph nodes draining the gut together with CD4^+^ and CD4^−^CD8α^−^ DCs in lymphoid tissues, appear to develop normally (Hacker et al., [@B48]; Ginhoux et al., [@B45]; Edelson et al., [@B37]). Through its action in regulating E protein binding, Id2 appears to plays a pivotal role in the maintenance of conventional DC identity. Multiple E proteins are expressed by DCs so precisely how these are regulated, and which E proteins (E2A, E2-2, or HEB) are the critical targets of Id2 is unclear. Understanding the balance between E proteins and Id proteins in cDCs will be required to understand why Id2 plays such an key role in CD8α^+^ and CD103^+^CD11b^−^ DCs and how differentiation of such subsets might be enhanced.

### Nfil3 (also known as E4BP4)

E4BP4 is a mammalian basic leucine zipper (bZIP) transcription factor that is required for the development of NK cells, and is a key regulator of cytokine production in other hematopoietic lineages (Gascoyne et al., [@B41]; Kamizono et al., [@B61]; Kashiwada et al., [@B62]; Kobayashi et al., [@B64]). In NK cells E4BP4 acts in a dose dependent manner downstream of the IL-15 receptor and regulates Id2 expression (Gascoyne et al., [@B41]; Kamizono et al., [@B61]). Thus, it has been found that induction of E4BP4 is important for the development of CD8α^+^ DCs (Kashiwada et al., [@B62]). *E4BP4^−/−^* mice exhibit impaired IL-12 production upon TLR3 activation, and failed to cross-prime CD8^+^ T cells against cell-associated antigens. CDPs deficient in E4BP4 displayed reduced BATF3 expression and enforced expression in these cells rescued CD8α^+^ DCs development *in vitro* (Kashiwada et al., [@B62]). Thus, E4BP4 is emerging as an important regulator of conventional DC development.

### Batf3

Batf3 is a bZIP transcription factor (also known as Jun dimerization protein p21SNFT) that represses NFAT--AP1 activity by competing with FOS for JUN dimerization (Dorsey et al., [@B34]; Echlin et al., [@B35]). It provoked enormous interest in the DC field when it was shown to play a critical role in DC differentiation. Indeed, it was the first description of a transcription factor that appeared to have an exclusive role in the development of the CD8α^+^ DC subset. The fact that deletion of Batf3 resulted in increased susceptibility to various pathogen infections such as West Nile virus, influenza virus, *Listeria monocytogenes*, and *Toxoplasma* *gondii* (Hildner et al., [@B52]; Desch et al., [@B32]; Edelson et al., [@B36]; Mashayekhi et al., [@B75]) and critically impaired cross-priming was striking (Hildner et al., [@B52]). More recently it has been described to be involved in the development of migratory cross-presenting CD103^+^CD11b^−^ DCs in peripheral lymphoid tissues (Edelson et al., [@B37]), but not in gut lymphoid tissue CD103^+^CD11b^+^ DCs (Bar-On et al., [@B9]). However, although *Batf3^−/−^* mice show a reduction in the frequency of CD8α^+^ DCs, particularly in the spleen, it is now clear that CD8α^+^ DCs are indeed present in the absence of Batf3 (Edelson et al., [@B36]; Jackson et al., [@B58]). Thus in contrast to the early suggestions, Batf3 appears to exclusively regulate the development of CD103^+^ DC while CD8α^+^ DC precursors develop although they seem unable to cross-present exogenous antigens to CD8^+^ T cells. This suggests that some stages in DC maturation may be perturbed in the absence of Batf3.

CD8α^−^ DC, monocyte-derived DC lineages, and transcriptional regulation
------------------------------------------------------------------------

Until recently, the capacity to cross-present antigens was a feature attributed almost exclusively to CD8α^+^ and CD103^+^ DCs. This distinction gained some foothold with the notion that particular DC subsets possess unique molecular machinery intrinsic to these subsets exclusively enabling them to cross-present (Schnorrer et al., [@B99]). However, in other settings, it was clear that non-CD8α^+^ lineage cells could also perform such functions. This was poignantly highlighted by the systematic characterization of the capacity for MoDCs to efficiently cross-present antigens, particularly in the inflammatory setting, demonstrated that induction of cross-presenting machinery could occur in different DC subsets when subjected to specific stimuli (Cheong et al., [@B24]).

Non-CD8α^+^ DC lineages are composed of DN and CD4^+^ DCs together with MoDCs. Much less is known about the transcription factors that regulate the fate decisions of these subsets although it is clear that at least the conventional subsets in this group are significantly influenced by IRF2 (Hida et al., [@B51]; Honda et al., [@B55]; Ichikawa et al., [@B56]; Arakura et al., [@B8]), IRF4 (Suzuki et al., [@B110]; Tamura et al., [@B112]), and RelB (Burkly et al., [@B19]; Wu et al., [@B116]). At least some of these pathways are also likely to regulate MoDCs. This could potentially happen through the role of IRF4 in coordinating signals from GM-CSF stimulation through the NF-κB pathway (Gilliet et al., [@B43]). It will be important to dissect the network of transcription factors that drive not only CD8α^−^ DC development but also function. This latter feature seems particularly important where a property such as cross-presentation is inducible and transcription factors such as Id2 and Batf3 are broadly expressed in the non-CD8α^−^ DC lineages but not obviously required for the development of these subsets. They may indeed be important for maturation or localization of DCs.

Nomenclature, DC Subsets, and the Tools Necessary for Precise Definitions
=========================================================================

Key steps in understanding DC subsets has come from detailed phenotypic characterization made possible through the development of novel antibodies combined with the power of flow cytometry. These descriptions have been significantly extended by elucidation of the anatomical localization of particular DC subset, the precursors from which they arise and the identification of unique or restricted functions that can now be attributed to particular DC subsets. For example, CD8α^+^ and CD103^+^ DCs are the dominant DC subsets that cross-present soluble and cell-associated antigens and present viral antigens to CD8^+^ T cells (den Haan and Bevan, [@B30]; Allan et al., [@B3]; Belz et al., [@B14],[@B15], [@B13]; Bedoui et al., [@B10]). While a number of seminal studies that have identified a new DC subset or function are critical to the development of the field, they have not always led to clarification of the contributions of DCs, or DC subsets, to immunoregulation of responses. This arises largely because surface markers or receptors are expressed by multiple DC subsets and in many instances, a broader range of immune cells. Thus, with regard to the capacity to cross-present antigens, MoDCs have recently also been discovered to be very efficient in shuttling antigen into this pathway, particularly in an inflammatory setting (Cheong et al., [@B24]).

One approach to this problem is to focus on the molecular wiring of cells -- that is, the transcription factors -- to develop a definitive map of DC identity (Satpathy et al., [@B95]). This approach indeed offers a way forward. However, deletion of specific DC populations is premised on the notion that presence or absence of a transcription factor results in a complete loss or alternately, exaggeration of DC subsets or their functions. Loss of some transcription factors such as Irf4, Irf8, and Id2 seem to demonstrate relatively definitive outcomes with complete loss of some DC subsets. Certainly, mice engineered to allow conditional deletion of a gene in a cell-specific manner (e.g., driven by CD11c) allows analysis of the intrinsic requirement for factors allows delineation of phenotypes that may arise due to extrinsic signals. Similar approaches have also been used where a cell-specific promoter drives conditional deletion of a cell type. A key example of this is the development of mice in which CD11c^+^ cells can be deleted by treating them with diptheria toxin (CD11c--DTR mice; Jung et al., [@B60]). This provides an elegant model for examination of cDCs but it was quickly realized that other cell types (such as inflamed lung epithelial cells) expressed CD11c and therefore generation of bone marrow chimeric mice was necessary to fully utilize this model without confounding effects (Sapoznikov and Jung, [@B94]).

In biology, this "black and white" model seldom reflects reality and it is not clear that DC differentiation into subsets is a purely linear process. Loss of the ability to detect a DC subset depends mainly on the same tools we have used to identify them in the first instance. These approaches do not generally distinguish between two important stages of developmental arrest -- firstly, complete ablation of a lineage, and secondly, the formation of the immediate precursors of that lineage that then fail to receive the necessary signals for DC progenitors to develop into fully matured cells in the peripheral tissues. The former situation identifies factors that are definitively required for the formation of a DC subset; the latter allows detailed dissection of the factors that influence the maturation and survival of DC subsets in the periphery. Distinguishing between these two cases is facilitated by the use of genetically modified mice in which a transcription factor is linked to a fluorescent reporter allowing rare precursor cells to be identified when most of the population does not survive to maturity. This was first identified in mice expressing green fluorescent protein linked to Ror(c)t, an important transcription factor for the development of lymphoid-tissue inducer (LTi) cells (Schmutz et al., [@B98]; Chappaz and Finke, [@B23]). Treatment of these reporter mice with IL-7/IL-7R mAb complexes revealed that progenitor cells were in fact formed in the absence of Ror(c)t but they did not develop into cells that could colonize and form secondary lymphoid tissues due to impaired IL-7 signaling. Similarly, Batf3 was initially described (Hildner et al., [@B52]) to unequivocally regulate the development of CD8α^+^ DCs and was later discovered to also regulate CD103^+^ DCs (Edelson et al., [@B37]). By analyzing the expression patterns of ID2 in *Batf3^−/−^* mice using the *Id2^GFP/GFP^* strain (Jackson et al., [@B58]), it was discovered that both *in vitro* and *in vivo* CD8α^+^ DC precursors do develop in the absence of Batf3 although their persistence, particularly in spleen, was diminished (Edelson et al., [@B36]; Jackson et al., [@B58]). These two examples highlight that careful dissection of phenotypes is critical and that complementary methods to analyze the expression of transcription factors and consequences of their loss provides a real strength in tackling the difficult questions of the future.

Overall, the factors that determine differentiation patterns of individual DC subsets with unique functions are complex. Establishment of the features that define an individual DC subset's identity, their maintenance and differentiation is unlikely to be simplistic and rely on a single phenotypic marker or transcription factor. A more likely scenario is that DC subset development is determined by combinatorial interactions between transcription factors to guide fate decisions (Lin et al., [@B70]; Wilson et al., [@B115]). Analyses of genome wide DNA-binding data will be critical for understanding precisely how these different transcription factors work together to define the different populations of DCs that are necessary to provide protective immunity.

Key Questions and Future Directions
===================================

Our current understanding of DC commitment and differentiation at a steady-state and during pathogen infection is limited, especially when compared to the extensive understanding of regulatory networks that guide fate decisions in B cells and CD4^+^ T cells. In addition, the mechanisms that guide the emergence inflammatory DCs and the induction of protective cross-presenting machinery offer a fertile field for discovery in the future. Collectively, understanding the complex and multilayered circuitry that integrates DC location, expression of surface molecules, components of the antigen processing and presentation machinery together with and understanding of the molecular wiring, and potential rewiring of DC subsets will be essential. This information will lead to a more complete picture of the roles of DCs and the DC network in maintaining immune tolerance and immunity and may prove pivotal to improvements in the clinical efficacy of therapeutic approaches. Solving the following, and other, critical questions in the field of DC biology will be instrumental in progressing discoveries in the field.

1.  Do individual transcription factors, or alternately, combinatorial transcriptional programs involving networks of transcription factors determine DC subset specification?

2.  How do DC subsets that emerge during inflammatory setting reflect those identified at steady-state?

3.  How is the constitutive cross-presenting machinery that maintains tolerance through presentation of self-antigens at steady-state, and is dominant in CD8α^+^ and CD103^+^ DCs during viral infection, induced in multiple DC subsets during inflammation or pathogen challenge?

4.  Can this inductive process be harnessed and how?

5.  How does the MDP engage the "DC program"?

6.  How does DC lifespan affect immunity?

7.  How is developmental plasticity is maintained to ensure immunity?

The challenge now is to develop the skill sets, tools, and technologies that will enable us to embark on dissection of these core features of DCs to open the pathway for targeted use of this cell type.
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